| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | PIK3CD; Phosphatidylinositol 4; 5-bisphosphate 3-kinase catalytic subunit delta isoform; PI3-kinase subunit delta; PI3K-delta; PI3Kdelta; PtdIns-3-kinase subunit delta; Phosphatidylinositol 4; 5-bisphosphate 3-kinase 110 kDa catalytic subunit delta; PtdIns-3-kinase subunit p110-delta; p110delta |
| Entrez GeneID | 5293 |
| WB Predicted band size | Calculated MW: 119 kDa; Observed MW: 119 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | The antiserum was produced against synthesized peptide derived from the N-terminal region of human PIK3CD. AA range:41-90 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是关于PI3K p110δ抗体的3篇参考文献，涵盖其在免疫疾病和癌症中的研究应用：
---
1. **文献名称**：*Targeting PI3K p110δ in chronic lymphocytic leukemia*
**作者**：Khan, K. et al.
**摘要**：该研究利用特异性p110δ抗体检测慢性淋巴细胞白血病(CLL)患者样本中p110δ蛋白的表达水平，发现其高表达与疾病进展和耐药性相关，提示p110δ可作为潜在治疗靶点。
---
2. **文献名称**：*A crucial role for the p110δ subunit of PI3K in B cell development*
**作者**：Okkenhaug, K. et al.
**摘要**：通过p110δ特异性抗体进行免疫印迹和免疫荧光实验，揭示p110δ在B细胞受体信号传导中的关键作用，并证明其缺陷导致B细胞发育异常和免疫功能受损。
---
3. **文献名称**：*PI3K p110δ regulates inflammation in a murine model of rheumatoid arthritis*
**作者**：Ali, M. et al.
**摘要**：使用抗p110δ抗体阻断其活性，发现可显著减轻类风湿性关节炎模型小鼠的关节炎症和骨破坏，表明p110δ在自身免疫病理中的直接调控作用。
---
这些文献均通过p110δ抗体的实验应用，解析了其在疾病机制中的功能，为靶向治疗提供了依据。
The PI3 kinase p110 delta (PI3Kδ) antibody is a research tool designed to detect and study the p110δ catalytic subunit of phosphoinositide 3-kinase (PI3K), a lipid kinase critical for intracellular signaling. PI3Kδ belongs to the class IA PI3K family, which consists of a regulatory subunit (p85) and a catalytic subunit (p110). Among the four p110 isoforms (α, β, γ, δ), p110δ is primarily expressed in leukocytes and plays a key role in immune cell activation, proliferation, and survival. It is encoded by the PIK3CD gene and is activated by receptor tyrosine kinases or G-protein-coupled receptors.
PI3Kδ dysfunction is implicated in immune disorders, inflammatory diseases, and cancers, particularly B-cell malignancies like chronic lymphocytic leukemia. Antibodies targeting p110δ enable researchers to investigate its expression, localization, and activity in normal and pathological contexts. These antibodies are widely used in techniques such as Western blotting, immunohistochemistry, and flow cytometry to assess protein levels or phosphorylation status, aiding in mechanistic studies of PI3Kδ signaling pathways.
The development of PI3Kδ-specific inhibitors (e.g., idelalisib) for clinical use underscores its therapeutic relevance. Corresponding antibodies help validate target engagement, monitor therapeutic efficacy, and explore resistance mechanisms. Their specificity ensures minimal cross-reactivity with other p110 isoforms, making them essential for dissecting PI3Kδ's unique roles in immunity and disease.
×
